secwatch.observer — SEC 8-K summary
======================================

Issuer:     Embecta Corp. (EMBC)
CIK:        0001872789
Form:       8-K
Filed at:   2026-03-20T23:59:59+00:00
Accession:  0000947871-26-000310
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Embecta to acquire Owen Mumford for up to £150M; adds drug-delivery platform
----------------------------------------------------------------------------

- Upfront cash payment of £100M at closing; up to £50M earnout based on Aidaptus net sales by end of 2028.
- Owen Mumford generated £69.4M revenue in FY2025; transaction expected to close in Embecta's fiscal Q3 2026.
- Deal unanimously approved by Embecta board; expected to be accretive to adjusted net income after FY2028.
- Acquisition positions Embecta in drug-delivery devices for chronic care (obesity, diabetes, autoimmune, anaphylaxis).
- Embecta plans to fund upfront with borrowings under its revolving credit facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1872789/000094787126000310/0000947871-26-000310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1872789/000094787126000310/ss6090062_8k.htm
  HTML page:      https://secwatch.observer/filing/0000947871-26-000310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer